Literature DB >> 19942921

Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?

Toni K Choueiri1, Michael B Atkins.   

Abstract

Sunitinib is a standard first-line therapy for patients with advanced or metastatic clear-cell renal cell carcinoma. in an expanded-access study, sunitinib has demonstrated clinical benefit with an acceptable safety profile in a population of patients that is representative of those seen in clinical practice.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19942921     DOI： 10.1038/nrclinonc.2009.170

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  7 in total

1.  Sunitinib in patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Brian I Rini; Ronald M Bukowski; Brendan D Curti; Daniel J George; Gary R Hudes; Bruce G Redman; Kim A Margolin; Jaime R Merchan; George Wilding; Michelle S Ginsberg; Jennifer Bacik; Sindy T Kim; Charles M Baum; M Dror Michaelson
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

2.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

3.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.

Authors:  Robert J Motzer; Jennifer Bacik; Barbara A Murphy; Paul Russo; Madhu Mazumdar
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

4.  Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.

Authors:  Martin E Gore; Cezary Szczylik; Camillo Porta; Sergio Bracarda; Georg A Bjarnason; Stéphane Oudard; Subramanian Hariharan; Se-Hoon Lee; John Haanen; Daniel Castellano; Eduard Vrdoljak; Patrick Schöffski; Paul Mainwaring; Alejandra Nieto; Jinyu Yuan; Ronald Bukowski
Journal:  Lancet Oncol       Date:  2009-07-15       Impact factor: 41.316

Review 5.  Treatment selection for patients with metastatic renal cell carcinoma.

Authors:  Michael B Atkins; Toni K Choueiri; Daniel Cho; Meredith Regan; Sabina Signoretti
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

Review 6.  Optimizing recent advances in metastatic renal cell carcinoma.

Authors:  Kevin D Courtney; Toni K Choueiri
Journal:  Curr Oncol Rep       Date:  2009-05       Impact factor: 5.075

7.  Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial.

Authors:  Tim Eisen; Stéphane Oudard; Cezary Szczylik; Gwenaelle Gravis; Hans Heinzer; Richard Middleton; Frank Cihon; Sibyl Anderson; Sonalee Shah; Ronald Bukowski; Bernard Escudier
Journal:  J Natl Cancer Inst       Date:  2008-10-07       Impact factor: 13.506
  7 in total
  1 in total

1.  Hereditary leiomyomatosis and renal cell cancer presenting as metastatic kidney cancer at 18 years of age: implications for surveillance.

Authors:  Karin Y van Spaendonck-Zwarts; Sadhanna Badeloe; Sjoukje F Oosting; Sjoerd Hovenga; Harry J F Semmelink; R Jeroen A van Moorselaar; Jan Hein van Waesberghe; Arjen R Mensenkamp; Fred H Menko
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.